Dr. Danila received his medical degree from the University of Chicago Pritzker School of Medicine and completed his residency at Stanford University Medical Center. Board-certified in Medical Oncology, Hematology, and Internal Medicine, he has authored numerous publications that have contributed to the understanding of biomarker-driven therapies in prostate cancer. His research emphasizes the identification of circulating tumor cells and other biomarkers to guide treatment decisions. Dr. Danila has been honored with awards from ASCO, AACR, and the Prostate Cancer Foundation for his leadership in clinical research and his contributions to improving prostate cancer treatment protocols. He is committed to mentoring emerging oncologists and fostering collaborative research initiatives at MSKCC.
Education
- Medical School: University of Chicago Pritzker School of Medicine
- Residency: Stanford University Medical Center
- Board Certification: Medical Oncology, Hematology, Internal Medicine
Awards
- ASCO Clinical Research Award – American Society of Clinical Oncology
- AACR Translational Research Award – American Association for Cancer Research
- Prostate Cancer Foundation Leadership Award
Professional Memberships and Affiliation
- American Society of Clinical Oncology (ASCO)
- American Association for Cancer Research (AACR)
- Prostate Cancer Foundation (PCF)
Clinical Experience
Dr. Daniel C. Danila specializes in the clinical management and research of prostate cancer at MSKCC. His expertise lies in the development and testing of new therapeutic agents through early-phase clinical trials. Dr. Danila focuses on identifying and validating biomarkers that predict treatment response, enabling more personalized and effective treatment strategies. His dedication to translational research bridges the gap between laboratory discoveries and clinical applications, enhancing patient outcomes and advancing the field of prostate cancer treatment.
Research and Publications
- “Circulating Tumor Cells as Biomarkers in Prostate Cancer” Journal: Journal of Clinical Oncology
- “Early-Phase Trials of Novel Agents in Prostate Cancer” Journal: Clinical Cancer Research
- “Biomarker Development for Prostate Cancer Treatment Response” Journal: Cancer Research
Dr. Daniel C. Danila
Medical Oncologist
Cancer Treated:
- 1275 York Avenue, New York, NY 10065
- (212) 639-2000
Dr. Danila received his medical degree from the University of Chicago Pritzker School of Medicine and completed his residency at Stanford University Medical Center. Board-certified in Medical Oncology, Hematology, and Internal Medicine, he has authored numerous publications that have contributed to the understanding of biomarker-driven therapies in prostate cancer. His research emphasizes the identification of circulating tumor cells and other biomarkers to guide treatment decisions. Dr. Danila has been honored with awards from ASCO, AACR, and the Prostate Cancer Foundation for his leadership in clinical research and his contributions to improving prostate cancer treatment protocols. He is committed to mentoring emerging oncologists and fostering collaborative research initiatives at MSKCC.